| First Author | Morton AJ | Year | 2001 |
| Journal | J Neurochem | Volume | 76 |
| Issue | 1 | Pages | 166-72 |
| PubMed ID | 11145989 | Mgi Jnum | J:67773 |
| Mgi Id | MGI:1931385 | Doi | 10.1046/j.1471-4159.2001.00059.x |
| Citation | Morton AJ, et al. (2001) Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. J Neurochem 76(1):166-72 |
| abstractText | Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder characterized by motor, emotional and cognitive dysfunction. There is no treatment or cure for this disease, and after the onset of symptoms, usually in the fourth decade of life, there is an inexorable decline to death. In many patients there is a complex deterioration of function before the onset of neuronal loss and, at least in mouse models, abnormalities in neurotransmission represent early events in the development of the disease. Here we describe the specific and progressive loss of complexin II from the brains of mice carrying the HD mutation (R6/2 line), and the later appearance of this protein in a subpopulation of neuronal intranuclear inclusions. Although the precise role of complexin II is still unclear, it is known to bind to the SNARE complex, and is therefore likely to be involved in the control of exocytosis. Our results suggest that changes in neurotransmitter release might contribute to the neuronal dysfunction seen in these mice. |
